A Phase 1 interventional study of Sacituzumab tirumotecan and Pembrolizumab in Non-small Cell Lung Cancer, Solid Tumors and Programmed Cell Death-1 (PD1, PD-1), sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 7 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 26 under way, 9 of them phase 3. sacituzumab tirumotecan · Carcinoma, Non-Small-Cell Lung.
Among the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, this one is the 22nd largest by planned enrollment, is one of 5 that started in 2023, is the only one in phase 1, reaches primary completion later than 14 of the 25 other live ones, and was the 5th registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →16 of the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
Guangdong Association of Clinical Trials · Sites in China
Ages 18+
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 9
First in 2020; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 115 across the 26 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
15 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc: 14 open now, 26 under way, 18 of them phase 3. Of 65 finished, 49 (75%) have results posted.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 78th largest by planned enrollment of the 88 interventional ones that give a count, is one of 8 that started in 2023, is one of 19 in phase 1, reaches primary completion later than 9 of the 25 other live ones, and was the 70th registered.
Merck & Co., Inc’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
8 of the studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448312Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT06711900Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | 2026-12 |
| NCT06670196Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | 2027-05 |
| NCT06074588Phase 3Merck Sharp & Dohme LLCSacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | 2027-05-10 |
| NCT06992739The First Affiliated Hospital of Xiamen UniversityTrilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) | 2027-03 |
Add all 8 to your calendar (.ics) → With an account.
Among the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Merck & Co., Inc’s 91 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in Japanese participants with advanced solid tumors or treatment-naïve advanced or metastatic non-small cell lung cancer (NSCLC).
Per protocol amendment 04, Arm 3: Pembrolizumab/Carboplatin + sacituzumab tirumotecan Combination Therapy was discontinued, and subsequently all Arm 3 procedures, recruitment, and descriptions were removed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive single doses of sacituzumab tirumotecan monotherapy once every 2 weeks (Q2W).
Biological: Sacituzumab tirumotecan · Drug: Supportive care measures
Participants receive sacituzumab tirumotecan Q2W in combination with pembrolizumab once every 6 weeks (Q6W).
Biological: Sacituzumab tirumotecan · Biological: Pembrolizumab · Drug: Supportive care measures
Sacituzumab tirumotecan injection powder for intravenous (IV) infusion.
Also known as: SKB264, MK-2870
Pembrolizumab solution for IV infusion.
Also known as: MK-3475
Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
A DLT is defined as any of the following: Grade 4 nonhematologic toxicity; Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia or lymphopenia; any nonhematologic AE ≥Grade 3 in severity (with some exceptions); any Grade 3 or Grade 4 nonhematologic laboratory value (if certain criteria are met); febrile neutropenia Grade 3 or Grade 4; a prolonged delay (\>2 weeks) in initiating sacituzumab tirumotecan second dose due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during DLT evaluation period; or any Grade 5 toxicity. All toxicities will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.
Time frame: Up to 21 days after each dose
Number of Participants Experiencing ≥1 Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to ~32 months
Number of Participants Discontinuing from Study Therapy due to AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to ~32 months
Area Under the Plasma Concentration-Time Curve (AUC) of sacituzumab tirumotecan -Antibody-Drug Conjugate (sacituzumab tirumotecan ADC)
The AUC of sacituzumab tirumotecan -ADC will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Maximum Plasma Concentration (Cmax) of sacituzumab tirumotecan-ADC
The Cmax of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Minimum Plasma Concentration (Cmin) of sacituzumab tirumotecan-ADC
The Cmin of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Apparent terminal half-life (t½) of sacituzumab tirumotecan-ADC
The t½ of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Time to Maximum Plasma Concentration (Tmax) of sacituzumab tirumotecan-ADC
The Tmax of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Clearance (CL) of sacituzumab tirumotecan-ADC
The CL of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Volume of Distribution (Vz) of sacituzumab tirumotecan-ADC
The Vz of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Accumulation Ratio (Rac) of sacituzumab tirumotecan-ADC
The Rac of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Area Under the Plasma AUC of sacituzumab tirumotecan-Total Antibody (sacituzumab tirumotecan-TAB)
The AUC of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Cmax of sacituzumab tirumotecan-TAB
The Cmax of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Cmin of sacituzumab tirumotecan-TAB
The Cmin of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
t½ of sacituzumab tirumotecan-TAB
The t½ of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Tmax of sacituzumab tirumotecan-TAB
The Tmax of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
CL of sacituzumab tirumotecan-TAB
The CL of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Vz of sacituzumab tirumotecan-TAB
The Vz of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Rac of sacituzumab tirumotecan-TAB
The Rac of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.
Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion
Cmax of sacituzumab tirumotecan-ADC Coadministered with Pembrolizumab
The Cmax of sacituzumab tirumotecan-ADC when coadministered with pembrolizumab will be determined in participants from Arm 2.
Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)
Cmin of sacituzumab tirumotecan-ADC Coadministered with Pembrolizumab
The Cmin of sacituzumab tirumotecan-ADC when coadministered with pembrolizumab will be determined in participants from Arm 2.
Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)
Rac of sacituzumab tirumotecan-ADC Coadministered with Pembrolizumab
The Rac of sacituzumab tirumotecan-ADC when coadministered with pembrolizumab will be determined in participants from Arm 2.
Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)
Cmax of sacituzumab tirumotecan-TAB Coadministered with Pembrolizumab
The Cmax of sacituzumab tirumotecan-TAB when coadministered with pembrolizumab will be determined in participants from Arm 2.
Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)
Cmin of sacituzumab tirumotecan-TAB Coadministered with Pembrolizumab
The Cmin of sacituzumab tirumotecan-TAB when coadministered with pembrolizumab will be determined in participants from Arm 2.
Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)
Rac of sacituzumab tirumotecan-TAB Coadministered with Pembrolizumab
The Rac of sacituzumab tirumotecan-TAB when coadministered with pembrolizumab will be determined in participants from Arm 2.
Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)
Cmax of KL610023 Coadministered with Pembrolizumab
The Cmax of KL610023 (free payload) when sacituzumab tirumotecan is coadministered with pembrolizumab will be determined in participants from Arm 2.
Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)
Rac of KL610023 Coadministered with Pembrolizumab
The Rac of KL610023 (free payload) when sacituzumab tirumotecan is coadministered with pembrolizumab will be determined in participants from Arm 2.
Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)
Objective Response Rate (ORR)
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.
Time frame: Up to ~39 months
Duration of Response (DOR)
DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause.
Time frame: Up to ~39 months
Incidence of Antidrug Antibodies (ADA) to sacituzumab tirumotecan
The incidence of ADA will be determined in participants from Arm 1 and Arm 2.
Time frame: Up to ~32 months
Incidence of Antidrug Antibodies (ADA) to pembrolizumab
The incidence of ADA will be determined in participants from Arm 2.
Time frame: Up to ~32 months
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started Oct 2023 (actual). Primary completion is estimated for Dec 2027, 50 months after the start.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 50 months is close to that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sacituzumab tirumotecan
Carcinoma, Non-Small-Cell Lung →